相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Adi Diab et al.
CLINICAL CANCER RESEARCH (2022)
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Tae Won Kim et al.
CLINICAL CANCER RESEARCH (2022)
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Omid Hamid et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
PHASE 1 DOSE ESCALATION AND DOSE EXPANSION STUDY OF AN AGONIST REDIRECTED CHECKPOINT (ARC) FUSION PROTEIN, SL-279252 (PD1-FC-OX40L), IN SUBJECTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS
Melissa Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Martin Gutierrez et al.
CLINICAL CANCER RESEARCH (2021)
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto et al.
TRANSLATIONAL ONCOLOGY (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Bonnie S. Glisson et al.
CLINICAL CANCER RESEARCH (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
New pathways in immune stimulation: targeting OX40
Carolina Alves Costa Silva et al.
ESMO OPEN (2020)
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
Pauline du Rusquec et al.
CANCER MANAGEMENT AND RESEARCH (2019)
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Rui Wang et al.
CLINICAL CANCER RESEARCH (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Immune Revolution: A Case for Priming, Not Checkpoint
Robert H. Vonderheide
CANCER CELL (2018)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking
Anna H. Turaj et al.
SCIENTIFIC REPORTS (2018)
From bench to bedside: Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors
Rui Wang et al.
CANCER RESEARCH (2018)
1192PEvaluation of OX40 receptor density, influence of IgG Isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade
H Jackson et al.
ANNALS OF ONCOLOGY (2018)
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
George Fromm et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
OX40: Structure and function - What questions remain?
Jane Willoughby et al.
MOLECULAR IMMUNOLOGY (2017)
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
Rajeev K. Shrimali et al.
CANCER IMMUNOLOGY RESEARCH (2017)
32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One
Journal for ImmunoTherapy of Cancer (2017)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer et al.
CLINICAL CANCER RESEARCH (2017)
Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators
Junjie Wu et al.
BMC CANCER (2016)
Engaging the immune system with GSK3174998, a potent anti-OX40 agonist antibody
Carlo Toniatti et al.
CANCER RESEARCH (2016)
First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results
Omid Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).
Scott Joseph Antonia et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Yannick Bulliard et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
Zhiqiang Guo et al.
PLOS ONE (2014)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function
Kui S. Voo et al.
JOURNAL OF IMMUNOLOGY (2013)
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
Yingzi Ge et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models
Simon N. Wood
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2011)
Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
Michael Croft
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
The significance of OX40 and OX40L to T-cell biology and immune disease
Michael Croft et al.
IMMUNOLOGICAL REVIEWS (2009)
A predictive probability design for phase II cancer clinical trials
J. Lack Lee et al.
CLINICAL TRIALS (2008)
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Silvia Piconese et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Critical aspects of the Bayesian approach to phase I cancer trials
Beat Neuenschwander et al.
STATISTICS IN MEDICINE (2008)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
OX40 ligand shuts down IL-10-producing regulatory T cells
Tomoki Ito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
分享论文
